Pleuropulmonary blastoma

A single-institution experience

Rajkumar Venkatramani, Marcio Malogolowkin, Larry Wang, Leo Mascarenhas

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Pleuropulmonary blastoma (PPB) is a rare primary intrathoracic mesenchymal malignancy that occurs exclusively in early childhood. Twelve patients were diagnosed with PPB (1 type I, 5 type II, and 6 type III) between 1979 and 2009 at our institution. Upfront complete tumor resection was successful in 5 of 6 patients. Six patients had biopsy followed by neoadjuvant chemotherapy, 2 had complete tumor resection, and 2 had microscopic residual disease after surgery. All patients received vincristine, dactinomycin, and cyclophosphamide chemotherapy. Eight received additional chemotherapy with doxorubicin, cisplatin, etoposide, or ifosfamide. Three patients received local irradiation. The 5-year event-free and overall survivals were 33%±14% and 42%±14%, respectively. Median time to progression was 8 months. Five of 9 patients with gross total resection survived, whereas all 3 with gross residual disease died. Three of 5 survivors did not receive radiation. A high index of suspicion for PPB must be maintained in all patients diagnosed with intrathoracic sarcoma in early childhood. Gross total resection is necessary for cure, and selected patients do not require radiation therapy.

Original languageEnglish (US)
JournalJournal of Pediatric Hematology/Oncology
Volume34
Issue number5
DOIs
StatePublished - Jul 1 2012
Externally publishedYes

Fingerprint

Drug Therapy
Neoplasms
Ifosfamide
Pleuropulmonary blastoma
Dactinomycin
Vincristine
Etoposide
Sarcoma
Doxorubicin
Cyclophosphamide
Cisplatin
Disease-Free Survival
Survivors
Radiotherapy
Radiation
Biopsy

Keywords

  • chemotherapy
  • microscopic residual disease
  • pleuropulmonary blastoma
  • radiation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Pleuropulmonary blastoma : A single-institution experience. / Venkatramani, Rajkumar; Malogolowkin, Marcio; Wang, Larry; Mascarenhas, Leo.

In: Journal of Pediatric Hematology/Oncology, Vol. 34, No. 5, 01.07.2012.

Research output: Contribution to journalArticle

Venkatramani, Rajkumar ; Malogolowkin, Marcio ; Wang, Larry ; Mascarenhas, Leo. / Pleuropulmonary blastoma : A single-institution experience. In: Journal of Pediatric Hematology/Oncology. 2012 ; Vol. 34, No. 5.
@article{e8a36b3236404a5c95a8191c77be97ff,
title = "Pleuropulmonary blastoma: A single-institution experience",
abstract = "Pleuropulmonary blastoma (PPB) is a rare primary intrathoracic mesenchymal malignancy that occurs exclusively in early childhood. Twelve patients were diagnosed with PPB (1 type I, 5 type II, and 6 type III) between 1979 and 2009 at our institution. Upfront complete tumor resection was successful in 5 of 6 patients. Six patients had biopsy followed by neoadjuvant chemotherapy, 2 had complete tumor resection, and 2 had microscopic residual disease after surgery. All patients received vincristine, dactinomycin, and cyclophosphamide chemotherapy. Eight received additional chemotherapy with doxorubicin, cisplatin, etoposide, or ifosfamide. Three patients received local irradiation. The 5-year event-free and overall survivals were 33{\%}±14{\%} and 42{\%}±14{\%}, respectively. Median time to progression was 8 months. Five of 9 patients with gross total resection survived, whereas all 3 with gross residual disease died. Three of 5 survivors did not receive radiation. A high index of suspicion for PPB must be maintained in all patients diagnosed with intrathoracic sarcoma in early childhood. Gross total resection is necessary for cure, and selected patients do not require radiation therapy.",
keywords = "chemotherapy, microscopic residual disease, pleuropulmonary blastoma, radiation",
author = "Rajkumar Venkatramani and Marcio Malogolowkin and Larry Wang and Leo Mascarenhas",
year = "2012",
month = "7",
day = "1",
doi = "10.1097/MPH.0b013e3182546adf",
language = "English (US)",
volume = "34",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Pleuropulmonary blastoma

T2 - A single-institution experience

AU - Venkatramani, Rajkumar

AU - Malogolowkin, Marcio

AU - Wang, Larry

AU - Mascarenhas, Leo

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Pleuropulmonary blastoma (PPB) is a rare primary intrathoracic mesenchymal malignancy that occurs exclusively in early childhood. Twelve patients were diagnosed with PPB (1 type I, 5 type II, and 6 type III) between 1979 and 2009 at our institution. Upfront complete tumor resection was successful in 5 of 6 patients. Six patients had biopsy followed by neoadjuvant chemotherapy, 2 had complete tumor resection, and 2 had microscopic residual disease after surgery. All patients received vincristine, dactinomycin, and cyclophosphamide chemotherapy. Eight received additional chemotherapy with doxorubicin, cisplatin, etoposide, or ifosfamide. Three patients received local irradiation. The 5-year event-free and overall survivals were 33%±14% and 42%±14%, respectively. Median time to progression was 8 months. Five of 9 patients with gross total resection survived, whereas all 3 with gross residual disease died. Three of 5 survivors did not receive radiation. A high index of suspicion for PPB must be maintained in all patients diagnosed with intrathoracic sarcoma in early childhood. Gross total resection is necessary for cure, and selected patients do not require radiation therapy.

AB - Pleuropulmonary blastoma (PPB) is a rare primary intrathoracic mesenchymal malignancy that occurs exclusively in early childhood. Twelve patients were diagnosed with PPB (1 type I, 5 type II, and 6 type III) between 1979 and 2009 at our institution. Upfront complete tumor resection was successful in 5 of 6 patients. Six patients had biopsy followed by neoadjuvant chemotherapy, 2 had complete tumor resection, and 2 had microscopic residual disease after surgery. All patients received vincristine, dactinomycin, and cyclophosphamide chemotherapy. Eight received additional chemotherapy with doxorubicin, cisplatin, etoposide, or ifosfamide. Three patients received local irradiation. The 5-year event-free and overall survivals were 33%±14% and 42%±14%, respectively. Median time to progression was 8 months. Five of 9 patients with gross total resection survived, whereas all 3 with gross residual disease died. Three of 5 survivors did not receive radiation. A high index of suspicion for PPB must be maintained in all patients diagnosed with intrathoracic sarcoma in early childhood. Gross total resection is necessary for cure, and selected patients do not require radiation therapy.

KW - chemotherapy

KW - microscopic residual disease

KW - pleuropulmonary blastoma

KW - radiation

UR - http://www.scopus.com/inward/record.url?scp=84862868368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862868368&partnerID=8YFLogxK

U2 - 10.1097/MPH.0b013e3182546adf

DO - 10.1097/MPH.0b013e3182546adf

M3 - Article

VL - 34

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 5

ER -